Peak-Muscle.com

Peak-Muscle.com (https://www.peak-muscle.com/forum/index.php)
-   Over 50 and beyond. (https://www.peak-muscle.com/forum/forumdisplay.php?f=160)
-   -   A Preliminary Investigation of the Enzymatic Inhibition of 5α-Reductase and Growth of (https://www.peak-muscle.com/forum/showthread.php?t=41209)

liftsiron 05-15-2020 01:14 PM

A Preliminary Investigation of the Enzymatic Inhibition of 5α-Reductase and Growth of
 
Original Article
A Preliminary Investigation of the Enzymatic Inhibition of 5α-Reductase and Growth of Prostatic Carcinoma Cell Line LNCap-FGC by Natural Astaxanthin and Saw Palmetto Lipid Extract In Vitro
Mark L. Anderson (Director of Research and Development)
Pages 17-26 | Published online: 20 Aug 2009




Abstract

Inhibition of 5oc-reductase has been reported to decrease the symptoms of benign prostate hyperplasia (BPH) and possibly inhibit or help treat prostate cancer. Saw Palmetto berry lipid extract (SPLE) is reported to inhibit 5a-reductase and decrease the clinical symptoms of BPH. Epidemiologic studies report that carotenoids such as lyco-pene may inhibit prostate cancer. In this investigation the effect of the carotenoid astaxanthin, and SPLE were examined for their effect on 5a-reductase inhibition as well as the growth of prostatic carcinoma cells in vitro.These studies support patent #6,277,417 B1.

The results show astaxanthin demonstrated 98% inhibition of 5a-reductase at 300 μg/mL in vitro.Alphastat, the combination of astaxanthin and SPLE, showed a 20% greater inhibition of 5a-reductase than SPLE alone in vitro.A nine day treatment of prostatic carcinoma cells with astaxanthin in vitroproduced a 24% decrease in growth at 0.1 mcg/mL and a 38% decrease at 0.01 mcg/mL. SPLE showed a 34% decrease at 0.1 mcg/mL.

Conclusions: Low levels of carotenoid astaxanthin inhibit 5a-reductase and decrease the growth of human prostatic cancer cells in vitro.Astaxanthin added to SPLE shows greater inhibition of 5a-reductase than SPLE alone in vitro.



Key Words: Prostate, Saw Palmetto, astaxanthin
Additional information
Author information
Mark L. Anderson
F. U. Alakbarov is Head Scientific Officer, expert in the Oriental and Folk Medicine, Institute of Manuscripts of the Azerbaijan Academy of Sciences, 8 Istiglaliyat str., Baku, 370001, Azerbaijan.
At the time of writing Liya Davydov was PharmD candidate, College of Pharmacy and Allied Health Professions, St. John’s University. Currently, she is Pharmacy Practice Resident, Mount Sinai Medical Center, New York, NY.
Ila Mehra Harris is Assistant Professor, Department of Pharmaceutical Care & Health Systems, College of Pharmacy, and Clinical Assistant Professor, Department of Family Practice & Community Health, Medical School, University of Minnesota, Minneapolis, MN.
Colin J. Briggs is Professor of Pharmacy, Faculty of Pharmacy, University of Manitoba. Recently he completed a secondment to Health Canada, as Senior Science Advisor in the Therapeutics Products Programme with special responsibility for complementary medicines.
Gemma Briggs is Research Assistant, IMPACT, The Injury Prevention Centre of Children’s Hospital, 501G-715 John Buhler Research Centre, Winnipeg, MB, Canada.
Mary Chavezis Professor of Pharmacy Practice, Director of Complementary Medicine Education and Research, The Center for the Advancement of Pharmacy Practice, Midwestern University, College of Pharmacy Glendale, Glendale, AZ 85308.


All times are GMT -5. The time now is 08:03 AM.

Powered by: vBulletin Version 3.8.11
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.